Lilly's Foundayo oral GLP-1 pill reaches US pharmacies at $149 a month for self-pay

Foundayo (orforglipron), Eli Lilly's once-daily oral GLP-1 pill for weight loss, is now available in the United States through retail pharmacies, telehealth providers and LillyDirect, the company said on April 9, 2026 ^[1]. The Food and Drug Administration approved the drug on April 1, 2026, for adults with obesity or with overweight plus a weight-related medical problem ^[1][3].

Self-pay patients start at $149 a month at the lowest dose, and people whose commercial insurance covers Foundayo may pay as little as $25 a month using a savings card, Lilly said ^[1]. Eligible Medicare Part D members may be able to get it for $50 a month beginning July 1, 2026 ^[1]. Lilly said it offers free home delivery through LillyDirect ^[1].

"Foundayo delivers meaningful weight loss – an average of 27 pounds at the highest dose – and we made the path from prescription to doorstep as simple as possible," said Ilya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities ^[1].

In the ATTAIN-1 trial, adults without diabetes who stayed on the highest dose lost an average of 27.3 pounds (12.4%) over 72 weeks, compared with 2.2 pounds (0.9%) on placebo. Counting every participant regardless of whether they stayed on treatment, average loss was 25 pounds (11.1%) versus 5.3 pounds (2.1%) with placebo ^[1]. That trial enrolled 3,127 people ^[1]. A second trial, ATTAIN-2, studied adults with obesity or overweight and type 2 diabetes and enrolled more than 1,600 people ^[1][3].

Foundayo is a small-molecule pill rather than a peptide, and Lilly says it is the only GLP-1 pill for weight loss that can be taken any time of day without restrictions on food or water ^[1]. Tablets come in six strengths, from 0.8 mg to 17.2 mg, with the dose raised in steps after at least 30 days at each level ^[3]. Foundayo is not recommended for use with other GLP-1 receptor agonist medicines, and it is not known whether it is safe and effective in children ^[1].

The label carries warnings about thyroid tumors including thyroid cancer, inflammation of the pancreas, gallbladder problems, dehydration leading to kidney problems, low blood sugar when taken with insulin or sulfonylureas, serious allergic reactions, and food or liquid getting into the lungs during surgery with anesthesia ^[1]. Lilly also says oral birth control pills may not work as well while taking Foundayo, and that a provider may recommend another form of birth control for 30 days after starting it and after each dose increase ^[1]. Common side effects include nausea, constipation, diarrhea, vomiting, indigestion, stomach pain, headache, swollen belly, tiredness, belching, heartburn, gas and hair loss ^[1].

Early prescription tracking pointed to a slower launch than Novo Nordisk's competing oral semaglutide, the Wegovy pill. Thirteen weeks in, Foundayo recorded 19,550 weekly prescriptions, compared with more than 105,000 for the Wegovy pill at the same point in its rollout, based on IQVIA data cited by Jefferies ^[2]. By the week reported Sept. 11, 2026, Foundayo reached about 47,500 weekly prescriptions while the Wegovy pill was near 183,000 ^[2]. Analysts noted IQVIA may be missing some Foundayo prescriptions filled through telehealth channels ^[2]. Lilly reported $98 million in second-quarter Foundayo sales, including $67 million in the U.S. ^[2].

Why it matters for patients

Cost and coverage remain the main hurdles. Lilly said about half of Americans with employer-sponsored insurance lack coverage for obesity management medications, which is why it expanded self-pay access ^[1]. For cash-paying patients, that means $149 a month at the starting dose; Lilly did not disclose what higher maintenance doses cost for self-pay ^[1].

For people who prefer not to inject, Foundayo adds a pill option, and its lack of food and water timing rules separates it from the Wegovy pill, which must be taken on an empty stomach ^[3]. Foundayo is a different molecule from semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound), and it should not be combined with another GLP-1 medicine ^[1]. Like other GLP-1 drugs, it is taken with a reduced-calorie diet and increased physical activity ^[1].

What happens next

July 1, 2026 is the date Lilly gave for the $50-a-month option for eligible Medicare Part D members ^[1]. Orforglipron is also being studied for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence; no results or timelines for those uses have been disclosed ^[1].